Sarepta Therapeutics (SRPT)
$127.93 1.96 (1.51%)
10:57 EDT SRPT Stock Quote Delayed 15 Minutes
Previous Close $129.88
Market Cap 8.38B
PE Ratio -43.51
Volume (Avg. Vol.) 163,400
Day's Range 127.67 - 131.00
52-Week Range 95.21 - 165.87
Dividend & Yield N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics News
- From InvestorPlace
- From the Web
If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.
If you follow the smart money, you end up following these stocks to buy. Here's what you should know about each.
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..
What's the next big thing in biotech? The answer is gene therapy and these five biotech stocks are leading the way.
According to Wall Street, these 7 stellar strong buy stock picks all boast over 30% upside potential from their current prices.
Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.
Sarepta Therapeutics (SRPT) stock was hit hard on Friday after reports claim one of its studies was put on hold due to an adverse event.
Sarepta Therapeutics (SRPT) stock was flying high on Thursday following the release of its earnings report for the second quarter of 2017.
Sarepta Therapeutics Inc (SRPT) stock was up on Thursday following an upgrade and price target increase from Leerink Swann.
These five biotech stocks are among some of the hottest movers as investors start 2017 with a rush into healthcare.
Biotech stocks and the SPDR S&P Biotech ETF (XBI) just shook off a major bugaboo in Hillary Clinton. The XBI ETF will soar as a result.
Medical is one of the sectors that is witnessing earnings and revenue growth this quarter, and these 5 healthcare stocks are set to beat
From Market News Video
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Booking Holdings Inc (BKNG), where a total volume of 7,586 contracts has been traded thus far today, a contract volume which is representative of approximately 758,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 231.2% of BKNG's average daily trading volume over the past month, of 328,185 shares..
From Market News Video
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!